Anti-sIL7R Antibody Therapy for Treating Autoimmune Diseases
Summary
The USPTO published patent application US20260098099A1 assigned to the Board of Regents of the University of Texas System, covering methods and compositions for anti-soluble interleukin-7 receptor (sIL7R) antibodies for treating autoimmune diseases including multiple sclerosis, lupus nephritis, type 1 diabetes, rheumatoid arthritis, and systemic lupus erythematosus. The application was filed on August 10, 2025.
What changed
The USPTO published patent application US20260098099A1 disclosing novel anti-sIL7R antibodies that selectively inhibit the soluble isoform of the interleukin-7 receptor without affecting membrane-bound IL7R (mIL7R). The antibodies target autoimmune diseases driven by sIL7R-mediated immune responses, including multiple sclerosis, lupus nephritis, type 1 diabetes, rheumatoid arthritis, and systemic lupus erythematosus. The therapeutic approach aims to reduce autoimmunity severity or prevent disease onset without triggering general immunosuppressive mechanisms.
For pharmaceutical and biotechnology companies, this patent application represents potential intellectual property considerations in the autoimmune disease therapeutics space. Entities developing immunomodulatory therapies should monitor the patent prosecution to assess potential freedom-to-operate implications or licensing opportunities. The selective targeting of sIL7R without affecting mIL7R represents a potentially novel mechanism that may impact competitive positioning in the biologics market for autoimmune disorders.
What to do next
- Monitor for patent grant and maintenance requirements
- Review patent claims for licensing opportunities
Archived snapshot
Apr 11, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ANTI-SOLUBLE INTERLEUKIN-7 RECEPTOR ANTIBODY THERAPY TO TREAT AUTOIMMUNE DISEASES
Application US20260098099A1 Kind: A1 Apr 09, 2026
Assignee
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Inventors
Mariano A. GARCIA-BLANCO, Gaddiel GALARZA-MUNOZ
Abstract
Recent studies indicate that sIL7R is involved in the development of autoimmune diseases. The present invention provides methods and compositions for a novel antibody therapeutic against the soluble isoform of the interleukin 7 receptor (sIL7R), a potent driver of self-destructive immune responses that cause autoimmune diseases including multiple sclerosis, lupus nephritis, type I diabetes, rheumatoid arthritis, systemic lupus erythematosus, and many other autoimmune diseases. The present invention includes antibodies specific for sIL7R that inhibit SIL7R, a driver of autoimmunity, without inhibiting mIL7R, thereby reducing the severity of or preventing autoimmunity without activating immunosuppressive mechanisms.
CPC Classifications
C07K 16/2866 A61K 45/06 A61P 37/02 A61K 2039/505 C07K 2317/31 C07K 2317/565 C07K 2317/76
Filing Date
2025-08-10
Application No.
19295663
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.